Zenon Biotech develops first‑in‑class mechano‑therapeutics that modulate cellular mechano‑sensors driving aging, inflammation and fibrosis. Leveraging a mechanobiology‑focused discovery platform, the company creates small‑molecule or biologic candidates aimed at disease‑modifying outcomes for fibro‑inflammatory conditions, and partners with pharma and biotech firms to advance these candidates through preclinical validation.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with fibro-inflammatory diseases such as chronic fibrosis, age‑related tissue degeneration, and persistent inflammation have limited treatment options because current drugs do not address the underlying cellular mechanosensing pathways that drive disease progression.
Solution
Zenon Biotech is developing a novel class of “mechano‑therapeutics” that target cellular mechano‑sensors involved in aging, inflammation, and fibrosis. By modulating these mechanotransduction pathways, the platform aims to intervene early in disease cascades, offering potential disease‑modifying effects rather than symptomatic relief. The discovery approach leverages extensive mechanobiology expertise to identify first‑in‑class drug candidates that can alter tissue remodeling and inflammatory signaling. Preclinical programs focus on validating target engagement and therapeutic benefit in relevant models of fibro‑inflammatory disorders. The company positions these agents as innovative solutions for unmet clinical needs where conventional pharmacology has failed.
Target Audience
Primary customers are pharmaceutical companies and biotech partners seeking novel therapeutic candidates for fibrosis, chronic inflammatory diseases, and age‑related tissue disorders.
Features
- Targeted modulation of cellular mechano‑sensors that regulate tissue stiffness, inflammation, and fibrotic remodeling
- First‑in‑class small‑molecule or biologic candidates designed to intervene in mechanotransduction pathways
- Integrated discovery platform combining mechanobiology insights with high‑throughput screening and structure‑based design
- Preclinical validation pipelines that assess target engagement, efficacy, and safety in fibrosis and inflammation models
- Potential for disease‑modifying outcomes across multiple fibro‑inflammatory indications